Articles from Humanetics Corporation

Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel approaches to tissue protection in oncology-related radiation exposure and mitigating the inflammatory response in pulmonary disease, today announced that the Company will be hosting a virtual panel on October 08, 2025, 1:30 pm EDT, entitled "Mitigating Tissue Damage in Radiation Oncology and Inflammation in Pulmonary Disease: Targeting Pathways of Tissue Injury and Inflammatory Response.”

Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel prophylactic Medical Countermeasures for military and civilian clinical applications, today announced that the Company will be presenting at the 71st Annual International Meeting of the Radiation Research Society being held September 21-24, 2025, at the Hilton Caribe, San Juan, Puerto Rico.

Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel prophylactic Medical Countermeasures for warfighters, first responders, and others at risk of radiation exposure from nuclear attacks or industrial accidents, today announced that Company scientists and members of the leadership team will be presenting and participating at the following conferences and events:

Humanetics Corporation announced today that executive management team members will participate in the Benchmark Company’s 5th Annual Healthcare House Call Virtual Investor Conference this week.

Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and patients with cancer and inflammatory lung diseases, today announced that its Chief Medical Officer, Rear Admiral Colin G. Chinn, MD, MHS, FACP (Ret.), will be a featured guest at a private industry, national security, and healthcare forum on February 27, 2025 in Naples, FL, entitled “Advancing America’s Future in Critical Industries.” Dr. Chinn will address “Breakthroughs in Radiation Protection for Military & Healthcare.”

Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in COVID-19 patients recently discharged from the hospital. BIO 300 is an oral drug that patients self-administer daily for 12 weeks following hospital discharge. The study compared the lung function, exercise capacity, and quality of life in COVID-19 survivors who received BIO 300 against a placebo group.

Humanetics Corporation (Humanetics) announced today that it was awarded an additional $5 million from the Department of Defense (DOD) to be added to its Other Transaction Authority (OTA) for Prototype Agreement that was received in Fall 2023. The Company aims to develop its drug, BIO 300, as a medical countermeasure to reduce bodily harm caused by acute exposure to radiation. The Company is advancing BIO 300 toward a New Drug Application (NDA) submission with pre-approval for emergency use authorization (pre-EUA) application as an early access point in the event a radiological/nuclear emergency occurs prior to full approval.

Humanetics Corporation (Humanetics) announced the publication of two noteworthy manuscripts detailing the development of BIO 300 as a radioprotective agent against acute radiation syndrome (ARS). These studies, published in peer-reviewed journals, highlight the radioprotective mechanisms of BIO 300, which is suitable for use by multiple routes of administration. The findings have implications for the development of BIO 300 as a radiation medical countermeasure (MCM) under the U.S. Food and Drug Administration's (FDA) Animal Rule.

Updates on the development of Humanetics Corporation’s (Humanetics) new drug candidate, BIO 300, were presented at the 2024 Military Health System Research Symposium (MHSRS), held August 26-29th in Kissimmee, Florida. MHSRS is the foremost scientific meeting of the U.S. Department of Defense (DOD), focusing on the unique medical needs of warfighters.

Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, will discuss BIO 300, its promising lead radioprotective drug candidate, at the BIO Investor Forum, Oct. 15-16, 2024. This event showcases drug development programs ready for partnering or venture funding, focusing on accelerating new therapeutic technologies into commercialization. It features panel discussions on policy, business, financing, and R&D, along with company presentations and BIO One-on-One Partnering™ meetings. The 2023 forum hosted over 1,600 partnering meetings. The conference takes place at the Fairmont Hotel in San Francisco. For more information: https://bif.bio.org/.

Minneapolis-based Humanetics Corporation (Humanetics), in collaboration with researchers within the U.S. Department of Defense (DOD) at the Armed Forces Radiobiology Research Institute (AFRRI), has entered into a new $3 million cooperative research agreement to continue advanced development of BIO 300, a medical countermeasure to protect military personnel and civilian first responders from harm caused by radiation exposure.

Humanetics Corporation, a clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA next week. This convention, known for its global reach and influence, provides a platform for industry leaders to showcase their innovations. Ronald J. Zenk, Chief Executive Officer, will present this information on Monday, June 3, 2024 (1:30 pm Company Presentation Theatre 3).

Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies, has announced that it will present and participate in several investor and partnering conferences in February. Ronald J. Zenk, Chief Executive Officer at Humanetics, along with members of management and the board of directors, will present an overview of the company and hold one-on-one meetings with potential investors and partners at the following conferences:

Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies, has announced the addition of Major General (Ret.) Barbara R. Holcomb, RN, BSN, MSN to its board of directors.

Humanetics Corporation, a leading innovator in medical countermeasures, is thrilled to announce the appointment of retired Rear Admiral Dr. Colin Chinn as its new Chief Medical Officer. In his new role, Dr. Chinn will bring his extensive medical and leadership experience to further enhance the company's commitment to excellence in the healthcare industry.

Humanetics Corporation (Humanetics) announced today that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. The funding will support a series of studies with its new drug candidate, BIO 300. BIO 300 is believed to prevent and mitigate acute and chronic inflammatory pulmonary diseases, including radiation toxicities. The studies will focus on the ability of BIO 300 to attenuate progressive pulmonary fibrosis as a potential treatment for idiopathic pulmonary fibrosis (IPF). IPF is a progressive and ultimately fatal lung disease that affects approximately 3 million people worldwide. IPF is associated with a particularly poor prognosis, with most patients succumbing to the disease within 3-5 years from diagnosis.

A recently published paper in the International Journal of Radiation Oncology – Biology – Physics (Red Journal) details encouraging results from a multicenter clinical study conducted with Humanetics Corporation’s (Humanetics) novel radioprotective drug, BIO 300, in patients with non-small cell lung cancer (NSCLC). Radiation therapy is a vital component of cancer treatment, delivering targeted doses of radiation to tumor sites to eliminate cancer cells. However, the challenge lies in minimizing the damage from radiation to surrounding healthy tissues, which can lead to debilitating side effects and limit treatment options. Humanetics aims to address this critical issue with BIO 300, which can safeguard normal tissues during radiotherapy without protecting the tumor, thereby enhancing patient outcomes and quality of life.

Humanetics Corporation (Humanetics) announced today that it was awarded a 5-year contract from the Department of Defense (DOD) to develop its drug, BIO 300, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation. The contract is in the form of an Other Transaction Authority (OTA) for Prototype Agreement. It includes a base period of $20 million for activities required to gain U.S. Food and Drug Administration (FDA) Emergency Use Authorization for the use of BIO 300 under a potential military emergency. In addition, the OTA agreement provides options for the DOD to fund all activities required to bring BIO 300 to full FDA approval.

Updates on the development of Humanetics Corporation’s (Humanetics) new drug candidate, BIO 300, were presented at the 2023 Military Health System Research Symposium (MHSRS), held August 14-17th. MHSRS is the U.S. Department of Defense’s (DOD) foremost scientific meeting focusing on the unique medical needs of Warfighters.

A recently published paper in Translational Lung Cancer Research details encouraging results from nonclinical studies conducted with Humanetics Corporation’s (Humanetics) novel radioprotective drug, BIO 300. The studies evaluated the therapeutic utility of BIO 300 when lung cancer undergoes treatment by radiation therapy. The positive results showcased that BIO 300 can protect normal tissues from collateral damage associated with radiotherapy without protecting the lung tumor, while potentially sensitizing the tumors to radiotherapy.

Humanetics Corporation (Humanetics) is pleased to announce the positive results from the independent Data Safety Monitoring Board (DSMB) review of its phase 2 clinical trial of BIO 300 in patients with COVID-19. The DSMB conducted an interim analysis of the unblinded trial data and determined that the study is not futile, and that it is reasonable to continue with the trial.

A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from studies conducted with Humanetics Corporation’s (Humanetics) new radioprotective drug, BIO 300, finding that BIO 300 is uniquely effective at protecting against radiation-induced lung injury.

Humanetics Corporation, a clinical-stage pharmaceutical company focused on novel products to improve outcomes for patients with cancer, presented at the MedInvest Oncology Investor Conference in New York City on December 15, 2022.

Humanetics Corporation (Humanetics) announced the publication of results from their recently completed phase 1 trial of BIO 300 Oral Powder in healthy volunteers in the journal Clinical Pharmacology in Drug Development (NCT04650555). BIO 300 Oral Powder is the Company’s medical countermeasure under development to prevent acute radiation syndrome (ARS). The article details results from the trial including safety, pharmacokinetics, and biomarkers in 34 healthy volunteers. No dose-limiting or dose-dependent toxicities were reported, and BIO 300 Oral Powder was found to be safe and well-tolerated. Biomarkers identified in this study were supportive of the radioprotective mechanism of BIO 300 Oral Powder. The trial was funded by the US Department of Defense’s Joint Warfighter Medical Research Program and conducted at Nucleus Network, LLC (St. Paul, MN).

Humanetics Corporation (Humanetics) presented data related to its new drug candidate, BIO 300, at the 68th Annual International Radiation Research Society Meeting, October 16-19, 2022. Michael Kaytor, PhD, Vice President of Research and Development for Humanetics, presented data related to BIO 300 Oral Powder, which is being developed as a medical countermeasure for use by military personnel, first responders, and at-risk civilian populations to prevent radiation damage. Protection from radiological events is of utmost importance given the current geopolitical climate.

Humanetics Corporation (Humanetics) announced today that it has received FDA clearance of its Investigational New Drug (IND) application for BIO 300 to mitigate erectile dysfunction in men undergoing radiation treatment for prostate cancer. This is the second IND for BIO 300 in oncology patients, and the fourth IND overall for the Company.

Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of Minneapolis businessperson Tom Jasper to its board of directors.

Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of renowned venture capitalist and life science industry expert Jake R. Nunn to the Company’s Board of Directors.

A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics (PK) studies conducted with Humanetics Corporation’s (Humanetics) new radioprotective drug, BIO 300. The studies, which were conducted by researchers at the University of Maryland Schools of Medicine and Pharmacy (UMB), compared the PK of BIO 300 using oral, subcutaneous, and intramuscular dosing. These nonclinical studies also examined the effect of radiation exposure on the PK of BIO 300. The researchers concluded that the effect of irradiation on the PK of BIO 300 is minimal, an important finding for use of the drug during radiation emergencies or during cancer radiotherapy treatments.

Minneapolis-based Humanetics Corporation (Humanetics) has entered into a new $5.1 million cooperative research agreement with the U.S. Department of Defense (DOD) to continue advanced development of BIO 300, a medical countermeasure to protect military personnel and first responders from the harm caused by radiation exposure.

Humanetics Corporation (Humanetics) has added two additional clinical sites to its long-haul COVID-19 study, which is focused on patients who were treated for severe COVID-19 and face the possible risk that their respiratory complications will lead to long-term impairment of lung function. The new sites that are now enrolling patients are Montefiore Medical Center (Bronx, NY) and the University of Texas Health Science Center at Houston (Houston, TX). These sites join existing sites at NYU Langone and the Houston Methodist Research Institute.

A recently published paper in the International Journal of Radiation Biology details results from a series of studies conducted with Humanetics Corporation’s (Humanetics) new radioprotective drug, BIO 300. In collaboration with researchers at the Uniformed Services University of the Health Sciences, within the United States Department of Defense (DoD), Humanetics compared the efficacy of BIO 300 to that of Neulasta®, an FDA-approved drug manufactured by Amgen Corporation, which is being stockpiled for nuclear or radiological emergencies. This nonclinical research showed that giving BIO 300 prior to exposure to lethal levels of radiation improved survival equal to Neulasta®, which is given after exposure. This protective effect of BIO 300 is of special interest to DoD, as they search for prophylactic agents that would allow warfighters to safely enter and operate in areas of known or potential nuclear or radiological risk. A protective drug like BIO 300 would also be ideal for first responders to nuclear accidents, such as those in Chernobyl, Ukraine, and Fukushima, Japan.

Humanetics Corporation (Humanetics) has appointed Mr. Douglas W. Bryce to its Board of Advisors. Mr. Bryce retired from federal service in December 2020 with more than 48 years of service to our nation. He served with the U.S. Marine Corps and the U.S. Army, and most recently retired from the position of Joint Program Executive Officer for Chemical, Biological, Radiological, and Nuclear Defense. At JPEO-CBRND, Mr. Bryce had material acquisition decision authority across all service arms for chemical, biological, radiological, and nuclear defense equipment, as well as medical diagnostic systems, drugs, and vaccines.

Humanetics Corporation (Humanetics), a clinical-stage pharmaceutical company pioneering radiation countermeasures, adjuvant oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of Dr. Karen Smith and Mr. Timothy Morris to the Company’s Board of Directors. Both Dr. Smith and Mr. Morris are highly respected executives who will add significant experience in pharmaceutical leadership and drug development as Humanetics’s proprietary drug BIO 300 gains traction for its potential to mitigate the harmful effects of radiation exposure on warfighters, first responders, and healthy tissues in certain cancer patients, as well as improve outcomes for COVID-19 long haulers.

Humanetics Corporation (Humanetics) announced today that it has completed a phase 1 trial of the Company’s medical countermeasure for acute radiation syndrome (ARS), BIO 300 Oral Powder (NCT04650555). The trial was conducted at Nucleus Network, LLC (St. Paul, MN) and successfully enrolled 34 healthy volunteers. The goal of the trial was to evaluate the safety, pharmacokinetics and pharmacodynamics of BIO 300 Oral Powder, which is under development for use by military and first responders to allow them to operate in areas of known or potential risk of radiation exposure. This trial was funded by the U.S. Department of Defense’s Joint Warfighter Medical Research Program.

Humanetics Corporation (Humanetics) announced today that BIO 300, a drug under development to increase survival in persons exposed to high levels of radiation, has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).

Humanetics Corporation (Humanetics) announced today that it has received a business development grant from Regenerative Medicine Minnesota to conduct a series of nonclinical studies with its investigational drug, BIO 300. The studies will evaluate the potential of BIO 300 to prevent metastasis of triple negative breast cancer to the lungs following radiotherapy.